SCHEMBL24007023

SCHEMBL24007023

COCc1c(OC)cc(N)cc1C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 3/20 0.41
▸ HTR2C P28335 2/20 0.41
▸ GAA P10253 3/20 0.37
▸ MAPT P10636 3/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ TSHR P16473 2/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ GLA P06280 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.33
▸ AURKA O14965 1/20 0.33
▸ KDR P35968 1/20 0.33
▸ AURKB Q96GD4 1/20 0.33
▸ CACNA1H O95180 1/20 0.33
▸ MBOAT4 Q96T53 2/20 0.32
▸ OXTR P30559 1/20 0.32
▸ HTR1A P08908 1/20 0.31
▸ ADRA2A P08913 1/20 0.31
▸ ADRA2B P18089 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24008096 0.81 ACHE (0.39) HTR2AHTR2CALDH1A1CACNA1HMBOAT4
SCHEMBL26011545 0.79 CACNA1H (0.38) HTR2AHTR2CCACNA1HCRHR1
SCHEMBL25747210 0.78 HTR2A (0.36) HTR2AHTR2CCACNA1HCRHR1
SCHEMBL26012392 0.74 CACNA1H (0.35) HTR2AHTR2CCACNA1HCRHR1
SCHEMBL25745999 0.74 HTT (0.42) MAPTHTTGLAPOLBALDH1A1
SCHEMBL25746004 0.73 AR (0.39) HTR2AHTR2CGAAKDM4EGLA
SCHEMBL24007020 0.73 HTR2A (0.33) HTR2AHTR2C
SCHEMBL16232928 0.70 MAPT (0.41) HTR2AHTR2CGAAMAPTKDM4E
SCHEMBL21553372 0.69 TSHR (0.48) GAAMAPTKDM4ETSHRMAPK1
SCHEMBL20354542 0.69 GAA (0.54) GAAMAPTKDM4ETSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2023-08-24 — — US disclosed
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2023-08-24 — — US disclosed
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors AJAX THERAPEUTICS, INC. (US) 2023-07-04 — — US disclosed
WO-2021226261-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. (US) 2021-11-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS JAK2, JAK3, STAT5B HTR2A 1660/4885HTR2C 1031/4885GAA 2648/4885
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors JAK2, JAK3, STAT5B HTR2A 1660/4885HTR2C 1031/4885GAA 2648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback